Section Arrow
Quote
INSM.NASDAQ
- Insmed Incorporated
Quotes are at least 15-min delayed:2026/07/15 17:23 EDT
After Hours
Last
 109.81
0 (0.00%)
Bid
109.77
Ask
109.79
High 109.81 
Low 109.81 
Volume 27.01K 
Regular Hours (Closed)
Last
 109.81
-0.3 (-0.27%)
Day High 
111.6 
Prev. Close
110.11 
1-M High
119.54 
Volume 
2.12M 
Bid
109.77
Ask
109.79
Day Low
108.34 
Open
111 
1-M Low
93.92 
Market Cap 
23.87B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 111.93 
20-SMA 106.16 
50-SMA 108.07 
52-W High 212.75 
52-W Low 90.39 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.76/0.91
Enterprise Value
24.44B
Balance Sheet
Book Value Per Share
3.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
606.42M
Operating Revenue Per Share
1.30
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.8529+0.0181+2.17%0.47PE
After Hours 0.835 -0.0179 -2.10%
LIMNLiminatus Pharma Inc0.1145+0.011+10.63%-- 
After Hours 0.12 +0.0055 +4.80%
IOVAIovance Biotherapeutics4.74+0.81+20.61%-- 
After Hours 4.7001 -0.0399 -0.84%
ERNAErnexa Therapeutics Inc.6.73+0.67+11.06%0.01PE
After Hours 7.2 +0.47 +6.98%
PHIOPhio Pharmaceuticals Corp0.8901-0.1399-13.58%-- 
After Hours 0.9199 +0.0298 +3.35%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.